Core Insights - NovoCure Limited achieved record net revenue of $655 million in 2025, driven by substantial active patient growth in international markets like France and Japan [4] - The company transitioned to a multi-indication platform following FDA approval of Optune Pax for locally advanced pancreatic cancer in a record 180-day review cycle [4] - Projected 2026 revenue is estimated to be between $675 million and $705 million, assuming low to mid-single-digit growth in the core glioblastoma (GBM) business and an additional $15 million to $25 million from new indications [4] Financial Performance - The gross margin decreased to 75% for 2025, attributed to lower prior-period collections and increased costs from HIV rates and tariffs [5] - The company is targeting a range of negative $20 million to breakeven for adjusted EBITDA in full-year 2026 through diligent expense management [4] Strategic Initiatives - The leadership team was restructured to combine scientific and clinical organizations under a dual Chief Innovation and Medical Officer role to accelerate R&D-to-clinical cycles [4] - Planned international expansion includes product launches in Japan, Spain, Czechia, and British Columbia to diversify the global revenue base [4] - Marketing spend for Optune Lua in the U.S. and Germany was rightsized due to slower-than-projected adoption in the non-small cell lung cancer market [4] Clinical Development - Anticipated clinical catalysts include Phase II PANOVA-4 top-line data in March and Phase III TRIDENT data in the second quarter of 2026 [4] - Enrollment for the Phase III KEYNOTE D58 trial in newly diagnosed GBM is expected to be completed by the end of 2026 [4] Operational Challenges - Addressed a temporary Medicare billing administrative issue, securing retroactive reinstatement to ensure no negative impact on revenue recognition [4] - Acknowledged a 1-2 year lag in routine commercial insurance coverage for new indications, requiring initial reliance on appeals and NCCN guideline inclusion [4]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Ganzhou Hemay Pharmaceutical Co., Ltd. 贛州和美藥業股份有限公司 (A joint stock company incorporated in the People's Republic of ...

Core Insights - Pliant Therapeutics is focused on closing out the BEACON-IPF trial, with topline data expected in the second quarter of 2025, while also making progress in its oncology program with PLN-101095 showing antitumor activity [1][2][7] First Quarter and Recent Developments - The company reported a net loss of $56.2 million for the first quarter of 2025, compared to a net loss of $47.0 million in the same quarter of the previous year, primarily due to increased operating expenses related to BEACON-IPF close-out activities [12] - Research and development expenses rose to $43.4 million from $37.1 million year-over-year, driven by the acceleration of close-out activities for BEACON-IPF [6][12] Oncology Program - Interim Phase 1 data from the PLN-101095 trial in combination with pembrolizumab demonstrated confirmed partial responses in three out of six patients treated at the highest dose, with tumor size reductions of 74%, 48%, and 42% in patients with non-small cell lung cancer, cholangiocarcinoma, and melanoma, respectively [4] - The trial is currently enrolling the fourth of five potential cohorts, evaluating PLN-101095 at a dose of 1000 mg administered three times daily [4] Corporate Highlights - A strategic realignment of workforce and operations was announced, including a 45% reduction in workforce, aimed at extending the cash runway to support clinical trials [5] - The realignment process is expected to be substantially completed by the second quarter of 2025 [5] Financial Position - As of March 31, 2025, the company had cash, cash equivalents, and short-term investments totaling $307.1 million [12] - Total current assets decreased from $362.3 million at the end of 2024 to $311.2 million [16]

Table of Contents As filed with the U.S. Securities and Exchange Commission on September 1, 2023. Registration No. 333-274292 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) 3841 Delaware (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 6272 W. 91st ...